Healthcare Stocks Today: Weekend Headlines, 2026 Themes, and What to Watch Before Monday’s Open

NEW YORK, Dec. 28, 2025, 1:22 p.m. ET — Market closed (weekend).

U.S. equity markets are shut for the weekend, but healthcare stocks are heading into Monday’s session with a fresh mix of catalysts—policy scrutiny around pharmacy practices, late-year sector rotation, and drug-development headlines—against a broader market backdrop that’s still flirting with major milestones.

The S&P 500 has been within striking distance of 7,000, and strategists say the “path of least resistance” for stocks has remained higher absent a shock—an environment that can favor healthcare when investors look for diversification beyond the most crowded growth trades. ^[1]

Why healthcare stocks are back in the conversation into year-end

Healthcare has quietly benefited from a market rotation that’s widened beyond mega-cap tech. Reuters notes that since early November, areas including healthcare have posted “solid gains,” a sign that investors have been reallocating toward sectors with more moderate valuations. Ameriprise chief market strategist Anthony Saglimbene told Reuters the moves point to rotation into more reasonably valued parts of the market, adding that more investors are buying into the idea that the economy is on solid footing. ^[2]

For healthcare investors, that matters because the sector often sits at the intersection of “defensive” demand (insurers, large pharma) and “innovation” optionality (biotech, medtech). In a year-end tape—where liquidity can be thin and positioning can dominate fundamentals—both characteristics can drive sharp single-session moves. ^[3]

The last 24–48 hours: key healthcare-stock headlines investors are digesting

1) Managed care and PBMs: Medicare refill waste raises scrutiny risk

A Wall Street Journal investigation published Saturday found that mail-order pharmacies—especially those owned by major insurers—sent Medicare patients large volumes of extra medication, producing an estimated $3 billion in waste from 2021 to 2023. The report specifically cites pharmacy operations tied to UnitedHealth, Humana, and CVS Health, and highlights how automatic 90‑day refills and early shipments can inflate surplus dispensing. ^[4]

Why it matters for healthcare stocks: investor focus tends to snap quickly from growth narratives to regulatory and reputational risk in managed care. Even without immediate enforcement action, stories like this can raise questions about business practices, compliance controls, and how pharmacy operations interact with Medicare quality metrics and reimbursement structures. ^[5]

2) Big Pharma pipeline risk: Johnson & Johnson halts an eczema program

Johnson & Johnson disclosed it discontinued a mid-stage study of an experimental atopic dermatitis (eczema) drug after it failed to meet efficacy goals in an interim analysis. Reuters reported the company said the treatment was well-tolerated but didn’t clear the efficacy “high bar” needed to advance development. ^[6]

Why it matters for healthcare stocks: in large-cap pharma, R&D setbacks rarely change the whole-company story overnight—but they can reshape investor expectations around pipeline depth and competitive positioning in crowded categories like immunology and dermatology, where incumbents and rivals already have multiple approved options. ^[7]

3) Markets context: low-volume conditions can amplify sector moves

Friday’s post‑Christmas session was light and conviction was limited. Reuters quoted Carson Group chief market strategist Ryan Detrick saying the market was “catching our breath” after a strong five-day rally, while noting the “Santa Claus rally” window can still tilt upward into early January. ^[8]

For healthcare stocks specifically, thin volume can exaggerate reactions to headlines—especially for mid-cap biotech and medtech names where flows can be more impactful than fundamentals on a given day. ^[9]

Forecasts and analysis: the big themes shaping healthcare stocks into 2026

Barron’s: five healthcare themes investors are watching next year

Barron’s laid out five major themes for 2026 that investors are already starting to price in:

Alzheimer’s research momentum (including renewed focus on trials tied to Eli Lilly’s Kisunla and implications for peers such as Biogen and Eisai)
UnitedHealth’s recovery narrative and upcoming guidance cadence
The next phase of GLP‑1 weight-loss competition, including oral versions from Novo Nordisk and Eli Lilly
“Biotech reawakening,” with M&A and the signal value of the 2026 J.P. Morgan Healthcare Conference
Medtech’s push-and-pull between solid fundamentals and macro/legislative uncertainty (with Medtronic cited as a standout) ^[10]

Reuters/BlackRock view: healthcare’s valuation case

In a Reuters ROI column, Helen Jewell (International CIO, Fundamental Equities, BlackRock) argued that investors looking for 2026 exposure beyond AI concentration may find opportunity in healthcare’s historically defensive earnings profile—while noting healthcare stocks traded at a sizable discount to global equities in recent analysis. ^[11]

Dealmaking and product catalysts still reverberating into year-end

Even though some of the week’s biggest healthcare catalysts hit earlier, they continue to shape sentiment:

Sanofi’s agreement to buy Dynavax for about $2.2 billion added fuel to the “biotech reawakening” narrative. William Blair analyst Matt Phipps told Reuters the acquisition made sense amid rising regulatory concerns around vaccines, and Reuters also noted J.P. Morgan analysts flagged Dynavax’s experimental shingles program as a potential longer-term revenue driver if early data holds up. ^[12]

These kinds of transactions can matter beyond the two tickers involved: they can reset valuation comps and revive takeover speculation across adjacent vaccine, immunology, and specialty-pharma names. ^[13]

What investors should know before the next session

1) The calendar: markets reopen Monday, then a holiday-shortened week

U.S. stock markets reopen Monday at the regular session hours (9:30 a.m. to 4:00 p.m. ET). ^[14]
This week is holiday-shortened with New Year’s Day on Thursday; Investopedia notes bond markets close early Wednesday, while stock markets keep normal hours. ^[15]

2) The macro catalyst that can spill into healthcare: Fed minutes

Minutes from the Federal Reserve’s December meeting are due Tuesday, and strategists say they could shape expectations for the path of rate cuts in 2026. Glenmede VP of investment strategy Michael Reynolds told Reuters the minutes may be “illuminating” as markets try to handicap how many cuts are coming. ^[16]

Why it matters for healthcare stocks: rate expectations influence valuation frameworks for longer-duration growth assets (biotech tools, high-multiple medtech) and can also affect insurers via the interplay of investment income, utilization trends, and policy expectations.

3) A practical watchlist for healthcare stocks into Monday

With the market closed today, investors typically use the weekend to map catalysts and risk:

Managed care / PBMs: watch for follow-ups or political responses tied to the Medicare refill-waste reporting; it’s the kind of story that can quickly evolve into hearings, audits, or new rules. ^[17]
Large-cap pharma pipeline tape: clinical-trial headlines and program halts can shift sentiment even when they don’t change near-term earnings. ^[18]
Biotech/M&A temperature: year-end is often quiet, but recent deal activity has kept investors alert for strategic buyers and conference-driven announcements in early January. ^[19]
Liquidity effects: thin trading can magnify moves—especially in smaller healthcare names—so gaps at Monday’s open can reflect positioning as much as fundamentals. ^[20]

Bottom line

Healthcare stocks are entering Monday’s session in a market that’s still broadly constructive—but increasingly selective. The sector has been a beneficiary of rotation beyond tech, yet near-term performance may hinge on a familiar healthcare mix: regulatory scrutiny (managed care and pharmacy), clinical-trial readouts (big pharma and biotech), and the macro rate narrative that can reshape valuations quickly as 2025 turns into 2026. ^[21]